http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 13 Aug 2026 07:18:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++AVAI+BIO%2C+INC.++++++++++++For%3A+Jun+30/26916402.html si-local-file:///var/storage/secattach/20260813/26916402.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++AVAI+BIO%2C+INC.++++++++++++For%3A+Jun+30/26916402.html Thu, 13 Aug 2026 07:18:00 -0400 AVAI O.41514066 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++AVAI+BIO%2C+INC.++++++++++++For%3A+Jun+30/26916402.html si-local-file:///var/storage/secattach/20260813/26916402.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++AVAI+BIO%2C+INC.++++++++++++For%3A+Jun+30/26916402.html Thu, 13 Aug 2026 07:18:00 -0400 AVAI O.41514066 http://www.streetinsider.com/Corporate+News/Insulinova+to+collaborate+with+San+Raffaele+on+diabetes+cell+therapy/26909509.html <p>Avaí Bio, Inc. (OTCQB: AVAI) and its joint venture partner Austrianova announced that their joint venture Insulinova has entered into a Research and Option Agreement with Ospedale San Raffaele S.r.l. (OSR) in Milan, Italy, to develop an encapsulated cell therapy for Type 1 and insulin-dependent Type 2 diabetes.</p><p>Under the agreement, the collaboration will combine OSR's stem cell-derived beta cell research with Austrianova's Cell-in-a-Box® encapsulation technology. The research program will be led by Professor Lorenzo Piemonti, Head of the Regenerative Medicine and Transplant Unit and Director of the Diabetes Research Institute at OSR, alongside Dr. Valeria Sordi, Head of the Beta http://www.streetinsider.com/Corporate+News/Insulinova+to+collaborate+with+San+Raffaele+on+diabetes+cell+therapy/26909509.html Wed, 12 Aug 2026 08:32:19 -0400 AVAI http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+Announce+Research+Collaboration+with+San+Raffaele+Hospital+to+Advance+Encapsulated+Cell+Therapy+for+Diabetes/26909412.html <p align="left" style="padding-left:0px;">LAS VEGAS, NEVADA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”) and Austrianova, its joint venture partner in Insulinova, today announced that Insulinova has entered into a Research and Option Agreement with Ospedale San Raffaele S.r.l. (OSR), a leading European biomedical research institution, to collaborate on the development of an encapsulated cell therapy for the treatment of Type 1 and insulin-dependent Type 2 diabetes. </p> <p align="left" style="padding-left:0px;">OSR, located in Milan, Italy, is internationally recognized for its leadership in diabetes research, regenerative medicine, and stem cell biology. The collaborative http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+Announce+Research+Collaboration+with+San+Raffaele+Hospital+to+Advance+Encapsulated+Cell+Therapy+for+Diabetes/26909412.html Wed, 12 Aug 2026 08:30:00 -0400 A.50210626 AVAI O.23744242 O.41514066 http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+Announce+Research+Collaboration+with+San+Raffaele+Hospital+to+Advance+Encapsulated+Cell+Therapy+for+Diabetes/26909412.html <p align="left" style="padding-left:0px;">LAS VEGAS, NEVADA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”) and Austrianova, its joint venture partner in Insulinova, today announced that Insulinova has entered into a Research and Option Agreement with Ospedale San Raffaele S.r.l. (OSR), a leading European biomedical research institution, to collaborate on the development of an encapsulated cell therapy for the treatment of Type 1 and insulin-dependent Type 2 diabetes. </p> <p align="left" style="padding-left:0px;">OSR, located in Milan, Italy, is internationally recognized for its leadership in diabetes research, regenerative medicine, and stem cell biology. The collaborative http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+Announce+Research+Collaboration+with+San+Raffaele+Hospital+to+Advance+Encapsulated+Cell+Therapy+for+Diabetes/26909412.html Wed, 12 Aug 2026 08:30:00 -0400 A.50210626 AVAI O.23744242 O.41514066 http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+Announce+Research+Collaboration+with+San+Raffaele+Hospital+to+Advance+Encapsulated+Cell+Therapy+for+Diabetes/26909412.html <p align="left" style="padding-left:0px;">LAS VEGAS, NEVADA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”) and Austrianova, its joint venture partner in Insulinova, today announced that Insulinova has entered into a Research and Option Agreement with Ospedale San Raffaele S.r.l. (OSR), a leading European biomedical research institution, to collaborate on the development of an encapsulated cell therapy for the treatment of Type 1 and insulin-dependent Type 2 diabetes. </p> <p align="left" style="padding-left:0px;">OSR, located in Milan, Italy, is internationally recognized for its leadership in diabetes research, regenerative medicine, and stem cell biology. The collaborative http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+Announce+Research+Collaboration+with+San+Raffaele+Hospital+to+Advance+Encapsulated+Cell+Therapy+for+Diabetes/26909412.html Wed, 12 Aug 2026 08:30:00 -0400 A.50210626 AVAI O.23744242 O.41514066 http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+Announce+Research+Collaboration+with+San+Raffaele+Hospital+to+Advance+Encapsulated+Cell+Therapy+for+Diabetes/26909412.html <p align="left" style="padding-left:0px;">LAS VEGAS, NEVADA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”) and Austrianova, its joint venture partner in Insulinova, today announced that Insulinova has entered into a Research and Option Agreement with Ospedale San Raffaele S.r.l. (OSR), a leading European biomedical research institution, to collaborate on the development of an encapsulated cell therapy for the treatment of Type 1 and insulin-dependent Type 2 diabetes. </p> <p align="left" style="padding-left:0px;">OSR, located in Milan, Italy, is internationally recognized for its leadership in diabetes research, regenerative medicine, and stem cell biology. The collaborative http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+Announce+Research+Collaboration+with+San+Raffaele+Hospital+to+Advance+Encapsulated+Cell+Therapy+for+Diabetes/26909412.html Wed, 12 Aug 2026 08:30:00 -0400 A.50210626 AVAI O.23744242 O.41514066 http://www.streetinsider.com/Globe+Newswire/Ava%C3%AD+Bio+and+Austrianova+Announce+Research+Collaboration+with+San+Raffaele+Hospital+to+Advance+Encapsulated+Cell+Therapy+for+Diabetes/26909412.html <p align="left" style="padding-left:0px;">LAS VEGAS, NEVADA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”) and Austrianova, its joint venture partner in Insulinova, today announced that Insulinova has entered into a Research and Option Agreement with Ospedale San Raffaele S.r.l. (OSR), a leading European biomedical research institution, to collaborate on the development of an encapsulated cell therapy for the treatment of Type 1 and insulin-dependent Type 2 diabetes. </p> <p align="left" style="padding-left:0px;">OSR, located in Milan, Italy, is internationally recognized for its leadership in diabetes research, regenerative medicine, and stem cell biology. The collaborative http://www.streetinsider.com/Globe+Newswire/Ava%C3%AD+Bio+and+Austrianova+Announce+Research+Collaboration+with+San+Raffaele+Hospital+to+Advance+Encapsulated+Cell+Therapy+for+Diabetes/26909412.html Wed, 12 Aug 2026 08:30:00 -0400 A.50210626 AVAI O.23744242 O.41514066 http://www.streetinsider.com/Globe+Newswire/Ava%C3%AD+Bio+and+Austrianova+Announce+Research+Collaboration+with+San+Raffaele+Hospital+to+Advance+Encapsulated+Cell+Therapy+for+Diabetes/26909412.html <p align="left" style="padding-left:0px;">LAS VEGAS, NEVADA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”) and Austrianova, its joint venture partner in Insulinova, today announced that Insulinova has entered into a Research and Option Agreement with Ospedale San Raffaele S.r.l. (OSR), a leading European biomedical research institution, to collaborate on the development of an encapsulated cell therapy for the treatment of Type 1 and insulin-dependent Type 2 diabetes. </p> <p align="left" style="padding-left:0px;">OSR, located in Milan, Italy, is internationally recognized for its leadership in diabetes research, regenerative medicine, and stem cell biology. The collaborative http://www.streetinsider.com/Globe+Newswire/Ava%C3%AD+Bio+and+Austrianova+Announce+Research+Collaboration+with+San+Raffaele+Hospital+to+Advance+Encapsulated+Cell+Therapy+for+Diabetes/26909412.html Wed, 12 Aug 2026 08:30:00 -0400 A.50210626 AVAI O.23744242 O.41514066 http://www.streetinsider.com/Globe+Newswire/Ava%C3%AD+Bio+and+Austrianova+Announce+Research+Collaboration+with+San+Raffaele+Hospital+to+Advance+Encapsulated+Cell+Therapy+for+Diabetes/26909412.html <p align="left" style="padding-left:0px;">LAS VEGAS, NEVADA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”) and Austrianova, its joint venture partner in Insulinova, today announced that Insulinova has entered into a Research and Option Agreement with Ospedale San Raffaele S.r.l. (OSR), a leading European biomedical research institution, to collaborate on the development of an encapsulated cell therapy for the treatment of Type 1 and insulin-dependent Type 2 diabetes. </p> <p align="left" style="padding-left:0px;">OSR, located in Milan, Italy, is internationally recognized for its leadership in diabetes research, regenerative medicine, and stem cell biology. The collaborative http://www.streetinsider.com/Globe+Newswire/Ava%C3%AD+Bio+and+Austrianova+Announce+Research+Collaboration+with+San+Raffaele+Hospital+to+Advance+Encapsulated+Cell+Therapy+for+Diabetes/26909412.html Wed, 12 Aug 2026 08:30:00 -0400 A.50210626 AVAI O.23744242 O.41514066 http://www.streetinsider.com/Globe+Newswire/Ava%C3%AD+Bio+and+Austrianova+Announce+Research+Collaboration+with+San+Raffaele+Hospital+to+Advance+Encapsulated+Cell+Therapy+for+Diabetes/26909412.html <p align="left" style="padding-left:0px;">LAS VEGAS, NEVADA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”) and Austrianova, its joint venture partner in Insulinova, today announced that Insulinova has entered into a Research and Option Agreement with Ospedale San Raffaele S.r.l. (OSR), a leading European biomedical research institution, to collaborate on the development of an encapsulated cell therapy for the treatment of Type 1 and insulin-dependent Type 2 diabetes. </p> <p align="left" style="padding-left:0px;">OSR, located in Milan, Italy, is internationally recognized for its leadership in diabetes research, regenerative medicine, and stem cell biology. The collaborative http://www.streetinsider.com/Globe+Newswire/Ava%C3%AD+Bio+and+Austrianova+Announce+Research+Collaboration+with+San+Raffaele+Hospital+to+Advance+Encapsulated+Cell+Therapy+for+Diabetes/26909412.html Wed, 12 Aug 2026 08:30:00 -0400 A.50210626 AVAI O.23744242 O.41514066 http://www.streetinsider.com/Corporate+News/Ava%C3%AD+Bio+and+Austrianova+agree+on+insulin+cell+supply+for+diabetes+JV/26792611.html <p>Avaí Bio, Inc. (OTCQB: AVAI) and its joint venture partner Austrianova announced they have reached an agreement with an undisclosed partner to supply insulin-producing cells for Insulinova, their shared diabetes therapy program.</p><p>Insulinova is a joint venture established between Avaí Bio and Austrianova in late 2025. The therapy combines cells that have undergone a cell-programming process to become insulin-producing with Austrianova's Cell-in-a-Box® encapsulation technology. Once implanted, the encapsulated cells are designed to produce insulin in response to glucose levels, targeting people with type 1 and insulin-dependent type 2 diabetes.</p><p>The agreement remains subject to the execution of definitive agreements and customary closing http://www.streetinsider.com/Corporate+News/Ava%C3%AD+Bio+and+Austrianova+agree+on+insulin+cell+supply+for+diabetes+JV/26792611.html Tue, 21 Jul 2026 08:03:14 -0400 AVAI http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+Reach+Agreement+for+Insulin-Producing+Cells+with+Internationally+Acclaimed+Partner+to+Advance+Diabetes+Therapy/26792574.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>July 21, 2026</chron></span> /PRNewswire/ -- Avaí <span>Bio, Inc.</span> (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced that, together with its joint venture partner Austrianova, it has successfully concluded negotiations and reached agreement on the terms of a collaboration with a premier, internationally acclaimed, partner to provide insulin-producing cells for Insulinova's groundbreaking diabetes therapy.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+Reach+Agreement+for+Insulin-Producing+Cells+with+Internationally+Acclaimed+Partner+to+Advance+Diabetes+Therapy/26792574.html Tue, 21 Jul 2026 08:00:00 -0400 AVAI O.41514066 http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+Reach+Agreement+for+Insulin-Producing+Cells+with+Internationally+Acclaimed+Partner+to+Advance+Diabetes+Therapy/26792574.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>July 21, 2026</chron></span> /PRNewswire/ -- Avaí <span>Bio, Inc.</span> (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced that, together with its joint venture partner Austrianova, it has successfully concluded negotiations and reached agreement on the terms of a collaboration with a premier, internationally acclaimed, partner to provide insulin-producing cells for Insulinova's groundbreaking diabetes therapy.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+Reach+Agreement+for+Insulin-Producing+Cells+with+Internationally+Acclaimed+Partner+to+Advance+Diabetes+Therapy/26792574.html Tue, 21 Jul 2026 08:00:00 -0400 AVAI O.41514066 http://www.streetinsider.com/PRNewswire/Ava%C3%AD+Bio+and+Austrianova+Reach+Agreement+for+Insulin-Producing+Cells+with+Internationally+Acclaimed+Partner+to+Advance+Diabetes+Therapy/26792574.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>July 21, 2026</chron></span> /PRNewswire/ -- Avaí <span>Bio, Inc.</span> (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced that, together with its joint venture partner Austrianova, it has successfully concluded negotiations and reached agreement on the terms of a collaboration with a premier, internationally acclaimed, partner to provide insulin-producing cells for Insulinova's groundbreaking diabetes therapy.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Ava%C3%AD+Bio+and+Austrianova+Reach+Agreement+for+Insulin-Producing+Cells+with+Internationally+Acclaimed+Partner+to+Advance+Diabetes+Therapy/26792574.html Tue, 21 Jul 2026 08:00:00 -0400 AVAI O.41514066 http://www.streetinsider.com/PRNewswire/Ava%C3%AD+Bio+and+Austrianova+Reach+Agreement+for+Insulin-Producing+Cells+with+Internationally+Acclaimed+Partner+to+Advance+Diabetes+Therapy/26792574.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>July 21, 2026</chron></span> /PRNewswire/ -- Avaí <span>Bio, Inc.</span> (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced that, together with its joint venture partner Austrianova, it has successfully concluded negotiations and reached agreement on the terms of a collaboration with a premier, internationally acclaimed, partner to provide insulin-producing cells for Insulinova's groundbreaking diabetes therapy.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Ava%C3%AD+Bio+and+Austrianova+Reach+Agreement+for+Insulin-Producing+Cells+with+Internationally+Acclaimed+Partner+to+Advance+Diabetes+Therapy/26792574.html Tue, 21 Jul 2026 08:00:00 -0400 AVAI O.41514066 http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++AVAI+BIO%2C+INC.++++++++++++For%3A+Mar+31/26767928.html si-local-file:///var/storage/secattach/20260714/26767928.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++AVAI+BIO%2C+INC.++++++++++++For%3A+Mar+31/26767928.html Tue, 14 Jul 2026 15:20:00 -0400 AVAI O.41514066 http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++AVAI+BIO%2C+INC.++++++++++++For%3A+Mar+31/26767928.html si-local-file:///var/storage/secattach/20260714/26767928.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++AVAI+BIO%2C+INC.++++++++++++For%3A+Mar+31/26767928.html Tue, 14 Jul 2026 15:20:00 -0400 AVAI O.41514066 http://www.streetinsider.com/SEC+Filings/Form++NT+10-K++++AVAI+BIO%2C+INC.++++++++++++For%3A+Mar+31/26709513.html si-local-file:///var/storage/secattach/20260630/26709513.html http://www.streetinsider.com/SEC+Filings/Form++NT+10-K++++AVAI+BIO%2C+INC.++++++++++++For%3A+Mar+31/26709513.html Tue, 30 Jun 2026 07:20:00 -0400 AVAI O.41514066 http://www.streetinsider.com/SEC+Filings/Form++NT+10-K++++AVAI+BIO%2C+INC.++++++++++++For%3A+Mar+31/26709513.html si-local-file:///var/storage/secattach/20260630/26709513.html http://www.streetinsider.com/SEC+Filings/Form++NT+10-K++++AVAI+BIO%2C+INC.++++++++++++For%3A+Mar+31/26709513.html Tue, 30 Jun 2026 07:20:00 -0400 AVAI O.41514066 http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+Complete+GMP+Master+Cell+Bank%2C+Begin+Viral+Testing+for+Cell-Based+Klotho+Anti-Aging+Therapy/26525516.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>May 20, 2026</chron></span> /PRNewswire/ -- Avaí <span>Bio, Inc.</span> (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced—together with its joint venture partner and global biotechnology firm, Austrianova— a major milestone in the Company's path to clinical trials, the completion of a <span>Master Cell Bank</span> (MCB) of genetically modified cells that overexpress the α-Klotho protein.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+Complete+GMP+Master+Cell+Bank%2C+Begin+Viral+Testing+for+Cell-Based+Klotho+Anti-Aging+Therapy/26525516.html Wed, 20 May 2026 08:45:00 -0400 A.50211433 AVAI O.17509382 O.41514066 http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+Complete+GMP+Master+Cell+Bank%2C+Begin+Viral+Testing+for+Cell-Based+Klotho+Anti-Aging+Therapy/26525516.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>May 20, 2026</chron></span> /PRNewswire/ -- Avaí <span>Bio, Inc.</span> (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced—together with its joint venture partner and global biotechnology firm, Austrianova— a major milestone in the Company's path to clinical trials, the completion of a <span>Master Cell Bank</span> (MCB) of genetically modified cells that overexpress the α-Klotho protein.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+Complete+GMP+Master+Cell+Bank%2C+Begin+Viral+Testing+for+Cell-Based+Klotho+Anti-Aging+Therapy/26525516.html Wed, 20 May 2026 08:45:00 -0400 A.50211433 AVAI O.17509382 O.41514066 http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+Complete+GMP+Master+Cell+Bank%2C+Begin+Viral+Testing+for+Cell-Based+Klotho+Anti-Aging+Therapy/26525516.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>May 20, 2026</chron></span> /PRNewswire/ -- Avaí <span>Bio, Inc.</span> (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced—together with its joint venture partner and global biotechnology firm, Austrianova— a major milestone in the Company's path to clinical trials, the completion of a <span>Master Cell Bank</span> (MCB) of genetically modified cells that overexpress the α-Klotho protein.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+Complete+GMP+Master+Cell+Bank%2C+Begin+Viral+Testing+for+Cell-Based+Klotho+Anti-Aging+Therapy/26525516.html Wed, 20 May 2026 08:45:00 -0400 A.50211433 AVAI O.17509382 O.41514066 http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+Complete+GMP+Master+Cell+Bank%2C+Begin+Viral+Testing+for+Cell-Based+Klotho+Anti-Aging+Therapy/26525516.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>May 20, 2026</chron></span> /PRNewswire/ -- Avaí <span>Bio, Inc.</span> (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced—together with its joint venture partner and global biotechnology firm, Austrianova— a major milestone in the Company's path to clinical trials, the completion of a <span>Master Cell Bank</span> (MCB) of genetically modified cells that overexpress the α-Klotho protein.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+Complete+GMP+Master+Cell+Bank%2C+Begin+Viral+Testing+for+Cell-Based+Klotho+Anti-Aging+Therapy/26525516.html Wed, 20 May 2026 08:45:00 -0400 A.50211433 AVAI O.17509382 O.41514066 http://www.streetinsider.com/PRNewswire/Ava%C3%AD+Bio+and+Austrianova+Complete+GMP+Master+Cell+Bank%2C+Begin+Viral+Testing+for+Cell-Based+Klotho+Anti-Aging+Therapy/26525516.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>May 20, 2026</chron></span> /PRNewswire/ -- Avaí <span>Bio, Inc.</span> (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced—together with its joint venture partner and global biotechnology firm, Austrianova— a major milestone in the Company's path to clinical trials, the completion of a <span>Master Cell Bank</span> (MCB) of genetically modified cells that overexpress the α-Klotho protein.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Ava%C3%AD+Bio+and+Austrianova+Complete+GMP+Master+Cell+Bank%2C+Begin+Viral+Testing+for+Cell-Based+Klotho+Anti-Aging+Therapy/26525516.html Wed, 20 May 2026 08:45:00 -0400 A.50211433 AVAI O.17509382 O.41514066